201. Eosinopenia as Predictor of Poor Outcome in Hospitalized COVID-19 Adult Patients from Waves 1 and 2 of 2020 Pandemic
- Author
-
Raphael Cauchois, Lea Pietri, Jean-Baptiste Dalmas, Marie Koubi, Thibaut Capron, Nadim Cassir, Nicola Potere, Ildo Polidoro, Rodolphe Jean, Pierre-André Jarrot, Baptiste Andre, Veronique Veit, Julien Carvelli, Vanessa Pauly, Pascal Chanez, Laurent Papazian, and Gilles Kaplanski
- Subjects
eosinopenia ,COVID-19 ,prognosis ,biomarker ,Biology (General) ,QH301-705.5 - Abstract
During SARS-CoV-2 infection, eosinopenia may reflect a hyperactive immune response. In this study of hospitalized COVID-19 patients, we aimed to better understand the prognostic value of severe eosinopenia (absolute eosinophil count = 0 G/L) and decipher its underlying mechanisms. We retrospectively analyzed the records of COVID-19 patients hospitalized from March to June 2020 in three university hospitals in Marseille, France. We assessed the association between severe eosinopenia and a composite poor outcome in these patients, including the need for oxygen supplementation at >6 L/min, ICU admission, and in-hospital death. Among the 551 COVID-19 patients included in this study, severe eosinopenia was found in 228 (51%) of them on admission to hospital and was associated with a composite poor outcome using multivariate analysis (OR = 2.58; CI95 [1.77–3.75]; p < 0.0001). We found a significant association between the presence of severe eosinopenia on admission and the elevation in C-reactive protein, ferritin, IP-10, and suPAR. The histological findings in a series of 37 autopsies from patients who died from severe COVID-19 and presented with severe eosinopenia showed no pulmonary eosinophil trapping. Severe eosinopenia can be a reliable biomarker associated with a composite poor outcome in hospitalized COVID-19 adult patients. It may reflect the magnitude of immune hyperactivation during severe-to-critical COVID-19.
- Published
- 2022
- Full Text
- View/download PDF